Design of drugs through a consideration of drug metabolism and pharmacokinetics
- 1 September 1994
- journal article
- review article
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 19 (3) , 193-199
- https://doi.org/10.1007/bf03188921
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- (S)- and (R)-8-(di-n-propylamino)-6,7,8,9-tetrahydro-3H-benz[e]indole-1-carbaldehyde: a new class of orally active 5-HT1A-receptor agonistsJournal of Medicinal Chemistry, 1993
- Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studiesJournal of Medicinal Chemistry, 1993
- Predicting the cytochrome P450 mediated metabolism of xenobioticsPharmacogenetics, 1993
- Benzazepinone calcium channel blockers. 2. Structure activity and drug metabolism studies leading to potent antihypertensive agents. Comparison with benzothiazepinonesJournal of Medicinal Chemistry, 1992
- Role of metabolism and pharmacokinetic studies in the discovery of new drugs—present and future perspectivesXenobiotica, 1992
- Bioanalytical data in decision making: Discovery and developmentXenobiotica, 1992
- Design of toxicokinetic studiesXenobiotica, 1990
- Pharmacokinetic-Pharmacodynamic Relationships of Oral Hypoglycaemic AgentsClinical Pharmacokinetics, 1989
- Synthesis of a series of compounds related to betaxolol, a new .beta.1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseasesJournal of Medicinal Chemistry, 1987
- Clinical Pharmacokinetics of Non-steroidal Anti-inflammatory DrugsClinical Pharmacokinetics, 1983